Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest PharmaTech's revenue for the
three
months ended in Jan. 2026 was $0.00 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jan. 2026 was $0.00 Mil.
Quest PharmaTech's Revenue per Share for the
three
months ended in Jan. 2026 was $0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2026 was $0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Quest PharmaTech's highest 3-Year average Revenue per Share Growth Rate was 58.70% per year. The lowest was -67.50% per year. And the median was -12.90% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Quest PharmaTech Revenue Related Terms
Quest PharmaTech Revenue Historical Data
* Premium members only.
The historical data trend for Quest PharmaTech's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Quest PharmaTech's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest PharmaTech Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Quest PharmaTech's Revenue distribution charts can be found below:
* The bar in red indicates where Quest PharmaTech's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest PharmaTech (QPTFF) has a Revenue of $0.00 Mil as of Jan. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Quest PharmaTech and its competitors.
Is Quest PharmaTech's Revenue too high?
Quest PharmaTech's current Revenue is $0.00 Mil.
How does Quest PharmaTech's Revenue compare to VRTX and REGN?
Quest PharmaTech's Revenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Quest PharmaTech and its competitors. Quest PharmaTech's current Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest PharmaTech stock overvalued right now?
Quest PharmaTech (QPTFF) has a current Revenue of $0.00 Mil. The current Revenue is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Quest PharmaTech (QPTFF), the current Revenue is $0.00 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quest PharmaTech Inc is developing targeted cancer therapy with its product (MAb AR9.6), under development for a novel target (truncated O-glycans on MUC16) discovered at the University of Nebraska Medical Center.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
QPTFF has been successfully added to your 
